Mizutani, Takashi
Morimoto, Ryota http://orcid.org/0000-0003-0931-3188
Isobe, Satoshi
Ito, Ryota
Araki, Takashi
Kimura, Yuki
Kazama, Shingo
Oishi, Hideo
Kuwayama, Tasuku
Hiraiwa, Hiroaki
Kondo, Toru
Okumura, Takahiro
Murohara, Toyoaki
Funding for this research was provided by:
Japan Society for the Promotion of Science
Article History
Received: 27 January 2023
Accepted: 13 April 2023
First Online: 5 June 2023
Declarations
:
: T.O. received research grants from Ono Pharmaceutical Co. Ltd., Bayer Pharmaceutical Co. Ltd., Daiichi-Sankyo Pharma Inc., and Amgen Astellas BioPharma K.K. outside of the submitted work. T.O. received honoraria from Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., and Medtronic Japan Co. Ltd. T.M. received lecture fees from Bayer Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., Sumitomo Pharma Co. Ltd., Kowa Co. Ltd., MSD K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K. K., Pfizer Japan Inc., Sanofi-Aventis K. K., and Takeda Pharmaceutical Co. Ltd. T.M. received an unrestricted research grant from the Department of Cardiology, Nagoya University Graduate School of Medicine, from Astellas Pharma Inc., Daiichi-Sankyo Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kowa Co. Ltd., MSD K. K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K. K., Otsuka Pharma Ltd., Pfizer Japan Inc., Sanofi-Aventis K. K., Takeda Pharmaceutical Co. Ltd., and Teijin Pharma Ltd. The authors declare that they have no conflicts of interest.